Add time:09/08/2019 Source:sciencedirect.com
BackgroundPemphigus Vulgaris (PV) is a vesiculobullous autoimmune disorder characterized by production of autoantibody against cellular adhesion molecules. The treatment of PV is based on the use of systemic corticosteroid along with immunosuppressive therapy, but sometimes there are limited resistant lesions not responding to conventional systemic therapy. This double-blind, randomized clinical trial was designed to evaluate the efficacy of intralesional rituximab versus Triamcinolone (cas 124-94-7) in treatment of the refractory scalp and mucosal pemphigus lesions.
We also recommend Trading Suppliers and Manufacturers of Triamcinolone (cas 124-94-7). Pls Click Website Link as below: cas 124-94-7 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View